This study is in progress, not accepting new patients
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
Summary
- Eligibility
- for people ages 0-50 (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- bluebird bio
- ID
- NCT03207009
- Phase
- Phase 3 Beta Thalassemia Research Study
- Study Type
- Interventional
- Participants
- About 18 people participating
- Last Updated